CG-598 / CG Invites - LARVOL DELTA

Local Stabilization of Hypoxia-Inducible Factor-1α Controls Intestinal Inflammation via Enhanced Gut Barrier Function and Immune Regulation. (PubMed, Front Immunol) - "The effectiveness of CG-598 was comparable to other immunosuppressive therapeutics such as TNF-blockers or JAK inhibitors. These results suggest that CG-598 could be a promising therapeutic candidate to treat inflammatory bowel disease."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • CD4 • CD73 • CDH1 • HIF1A • IL10 • TFF3

Newly added product (Korea Biomedical Review) - Preclinical, IBD

Pipeline update

Crystal Genomics confirms efficacy of inflammatory bowel disease treatment (Korea Biomedical Review) - "Crystal Genomics said that it has confirmed the efficacy of CG-598, an inflammatory bowel disease (IBD) treatment candidate, through a pre-clinical trial. As a result of animal experiments on rats, the company observed the therapeutic effect of CG-598 in both the artificially created dinitrobenzene sulfonic acid-induced colitis model and dextran sulfate sodium-induced colitis model."

Preclinical